Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers. Now the UK pharma is aiming to build ...

Currently, five PARP inhibitor drugs are running in clinical trials for approval. All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with ...

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer. The alliance is important for Tesaro, which is ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...

To Know in detail about the PARP Inhibitors market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: PARP Inhibitors Market Forecast Report Some of the key insights of ...

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized starting doses, may improve patient outcomes.

One important problem that may arise during PARP inhibitor treatment is the development of resistance. Even BRCA-deficient mouse tumors were reported to acquire resistance to PARP inhibitors.